Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
Background Targeting the PD-1/PD-L1/L2 (programmed cell death protein 1/programmed cell death ligand 1/ligand 2) pathway combined with other immunosuppressive signalings, such as CD73/A2aR (A2a adenosine receptor) adenosine signaling, has emerged as a promising strategy for cancer treatment. The gen...
Saved in:
Main Authors: | Tingting Zhang, Zhenzhen Zhang, Xiubao Ren, Jin He, Zhengzi Qian, Bin Meng, Lei Jiao, Hengqi Liu, Lanfang Li, Lihua Qiu, Shiyong Zhou, Wenchen Gong, Huilai Zhang, Xianhuo Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-04-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/4/e004114.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The age-adjusted international prognostic index 2 (A-FLIPI2) for elderly patients with follicular lymphoma
by: Jiesong Wang, et al.
Published: (2025-02-01) -
PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1
by: Lvyun Zhu, et al.
Published: (2024-12-01) -
PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01) -
Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01) -
PD-L1 antibodies-armed exosomal vaccine for enhanced cancer immunotherapy by simultaneously in situ activating T cells and blocking PD-1/PD-L1 axis
by: Xinyue Dai, et al.
Published: (2022-12-01)